X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

MOLECULAR CANCER THERAPEUTICS

期刊標題檢索 MOL CANCER THER 最新評論: Hello, I would like to inquire about the fee regulations for this jour... (2024-09-29)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[MOLECULAR CANCER THERAPEUTICS]您好,您是該頁面的第 76759 位訪客。

期刊簡介
期刊名稱MOLECULAR CANCER THERAPEUTICS MOLECULAR CANCER THERAPEUTICS
LetPub Score
7.9
50 ratings
Rate

Reputation
8.8

Influence
6.7

Speed
9.6

期刊簡稱MOL CANCER THER
ISSN1535-7163
E-ISSN1538-8514
h-index157
CiteScore
CiteScoreSJRSNIPCiteScore Rank
11.202.2701.016
Subject fieldQuartilesRankPercentile
Category: Medicine
Subcategory: Oncology
Q148 / 404
Category: Medicine
Subcategory: Cancer Research
Q141 / 230

自引率 (2023-2024)0.00%自引率趨勢
掲載範囲
Molecular Cancer Therapeutics will focus on basic research that has implications for cancer therapeutics in the following areas: Experimental Cancer Therapeutics, Identification of Molecular Targets, Targets for Chemoprevention, New Models, Cancer Chemistry and Drug Discovery, Molecular and Cellular Pharmacology, Molecular Classification of Tumors, and Bioinformatics and Computational Molecular Biology. The journal provides a publication forum for these emerging disciplines that is focused specifically on cancer research. Papers are stringently reviewed and only those that report results of novel, timely, and significant research and meet high standards of scientific merit will be accepted for publication.
官方網站http://mct.aacrjournals.org/
在線稿件提交http://mct.msubmit.net/cgi-bin/main.plex
開放訪問No
出版商American Association for Cancer Research Inc.
主題領域医学
出版國/地區UNITED STATES
發行頻率月刊
創刊年2001
每年文章數116每年文章數趨勢
黃金OA百分比32.75%
Web of Science 四分位
2023-2024
WOS Quartile: Q1

CategoryEditionJIF QuartileJIF RankingJIF Percentage
ONCOLOGYSCIEQ161/322
索引 (SCI or SCIE)Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1535-7163%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: Average 3 Month(s)
競爭力 *來自作者的數據: About 50%
參考鏈接
相關期刊 【MOLECULAR CANCER THERAPEUTICS】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    CA-A CANCER JOURNAL FOR CLINICIANSH-index: 144

    CiteScore: 873.20
    Nature Reviews Clinical OncologyH-index: 127

    CiteScore: 99.40
    NATURE REVIEWS CANCERH-index: 396

    CiteScore: 111.90
    ANNALS OF ONCOLOGYH-index: 210

    CiteScore: 63.90
    CANCER CELLH-index: 295

    CiteScore: 55.20
    JOURNAL OF CLINICAL ONCOLOGYH-index: 494

    CiteScore: 41.20
    LANCET ONCOLOGYH-index: 274

    CiteScore: 62.10
    CANCER RESEARCHH-index: 411

    CiteScore: 16.10
    SEMINARS IN CANCER BIOLOGYH-index: 134

    CiteScore: 26.80
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCHH-index: 67

    CiteScore: 18.20
    學科內最受檢索的期刊 頁面查看次數
    CANCER LETTERS338228
    CANCER RESEARCH313880
    Asian Pacific Journal of Cancer Prevention259139
    BMC CANCER249494
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH198306
    INTERNATIONAL JOURNAL OF CANCER196332
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY183973
    CLINICAL CANCER RESEARCH183719
    ONCOLOGY REPORTS180245
    CA-A CANCER JOURNAL FOR CLINICIANS164570
  •  

    MOLECULAR CANCER THERAPEUTICS MOLECULAR CANCER THERAPEUTICS
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    2    3    下一頁    末頁  (頁
/3)
  [MOLECULAR CANCER THERAPEUTICS] 的評論撰寫評論
作者: 东京天祥


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-09-29 09:36:41 評論於
Hello, I would like to inquire about the fee regulations for this journal. Do I only need to pay the OA fee, or do I also need to pay publication fees? Are publication fees a combination of basic publication fees and image fees? If my article has 8 images, then I would need to pay 1200 + 8*652 = 6200 USD.
(0) 讚! | 东京天祥

作者: Deirdre Gibbon


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-09-18 18:18:57 評論於
How is everything going?
(0) 讚! | Deirdre Gibbon

作者: 气甲鹏鹍


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-09-17 10:33:38 評論於
My as well, have you received the email?
(0) 讚! | 气甲鹏鹍

作者: Dean Kennedy


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-09-11 23:39:55 評論於
How did I go from "under review" back to this step again? What does this mean?
(0) 讚! | Dean Kennedy

作者: Adelaide Lawson


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-08-02 08:08:16 評論於
The quality of the manuscript and the editing efficiency are related, so pay more attention to the status of the manuscript.
(0) 讚! | Adelaide Lawson

作者: 通幽金五


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-07-25 11:56:20 評論於
How long does the "Under Editorial Consideration" status last?
(0) 讚! | 通幽金五

作者: Xiong—


領域: 医学
審稿時間: 2.0 month(s)
結果: 修改後接受


撰寫評論

2022-07-02 22:39:07 評論於
The first trial takes one and a half months, two months for revision, and the second trial is accepted within one week.
(0) 讚! | Xiong—

作者: Yvonne Zhan


領域: 医学
審稿時間: 2.0 month(s)
結果: 修改後接受


撰寫評論

2022-07-02 22:12:26 評論於
The magazine under the American Cancer Society has fewer publications by Chinese people, making it more difficult to submit. The reviewers provide constructive feedback, and making improvements according to their suggestions has enhanced the experimental articles.
(0) 讚! | Yvonne Zhan

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 08:52:15 評論於
The majority of journals use online submissions. Authors need to prepare the manuscript, tables, and attachments in advance. The submission process generally follows: go to the journal's website, open "submit paper", register an account as the corresponding author, then login as an author, follow the instructions, download the pdf, ensure accuracy, and submit
(0) 讚! | 维尔娜菲茨杰拉德

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 08:00:37 評論於
Most journals require submissions in Word format, but there are also some that request PDF
(0) 讚! | 维尔娜菲茨杰拉德

作者: 北国博达


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-28 19:21:00 評論於
Should I upload the article in Word or PDF format?
(0) 讚! | 北国博达

作者: 破戒阳平


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-26 23:56:33 評論於
How should an article be uploaded?
(0) 讚! | 破戒阳平

作者: Paula Rayleign


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-07-31 13:34:19 評論於
Review speed: 2.0 | Submission acceptance rate: 50.0
Emphasized research direction: experience sharing in cancer metastasis research: original images need to be uploaded. The review speed is okay, and reviewers are fair. Although not as good as the top journals, AACR's journal is still trustworthy
(0) 讚! | Paula Rayleign

作者: yi-----


領域: 医学
審稿時間: 1.0 month(s)
結果: 修改後接受


撰寫評論

2021-03-18 23:44:31 評論於
First review took one month, second review took one and a half months. From submission to online publication, it took a total of eight months (07/2020 - 03/2021).
(0) 讚! | yi-----

作者: 擒龙俊鑫


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2020-06-27 10:40:43 評論於
Excuse me, there is a big difference between target protein and internal reference, it's wasteful to use one membrane for antibody blotting, so I cut the membrane before antibody blotting. Is this okay?
(0) 讚! | 擒龙俊鑫

作者: Donna Hodge


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2020-05-14 10:56:40 評論於
Review speed: 6.0 | Submission success rate: 25.0 Experience sharing: Too long
(0) 讚! | Donna Hodge

作者: 帕梅拉潘兹


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-06-30 18:50:57 評論於
Color pictures are more expensive. I have a figure of 6, with 2 black and white pictures and 4 color pictures. One color picture costs $625, and the publication fee is $1200
(0) 讚! | 帕梅拉潘兹

作者: 重阳欣悦


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-06-16 08:24:52 評論於
Hello, may I ask how much is the layout fee for the magazine?
(0) 讚! | 重阳欣悦

作者: Bevis Bart


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-06-05 10:46:40 評論於
Basically, no magazine will require three results. The reason is well known to everyone. The magazines also know that if they require three results, no one will submit. I don't know about the CNS journal, but sub-journals only require results once. The current wb requires uncropped film, and the editor will ask for it before acceptance
(0) 讚! | Bevis Bart

作者: 重阳泰宁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-05-23 12:00:39 評論於
Review speed: 2.0 | Submission hit rate: 25.0 Experience sharing: What original data needs to be provided? Are the results of the wb three times needed? When to provide? Do you need to submit as is or after modification?
(0) 讚! | 重阳泰宁

作者: 帕梅拉潘兹


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-04-29 21:16:10 評論於
Review speed: 1.0 | Submission hit rate: 25.0 Experience sharing: Just received a manuscript. First submission in June, rejected without external review, but was told that it could be resubmitted with additional experiments; submitted again in July after the completion of the experiments, rejected again, and was told that relevant sequences must be provided for external review; resubmitted in mid-September, external review comments received on October 30, minor revisions, and returned after 2 months of revision. Revised on January 7, 2019, officially accepted on April 26
(0) 讚! | 帕梅拉潘兹

作者: 傲寒曼吟


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-03-31 21:53:38 評論於
It's been ten days. How are you feeling now?
(0) 讚! | 傲寒曼吟

作者: 东风谷宏帅


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-03-20 18:11:03 評論於
It has been several days since the quality control, but there have been no changes. Has anyone else experienced this situation?
(0) 讚! | 东风谷宏帅

作者: 东风谷宏帅


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-03-15 13:59:44 評論於
How did your QC issue turn out in the end? I also encountered a similar issue, is it normal?
(0) 讚! | 东风谷宏帅

作者: Bevis Bart


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2019-02-14 08:38:22 評論於
It's a big loss for CCR to switch to this one downstairs
(0) 讚! | Bevis Bart

首頁    上一頁    1    2    3    下一頁    末頁  (頁
/3)

開始撰寫 [MOLECULAR CANCER THERAPEUTICS] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*